AbbVie Inc. vs Gilead Sciences, Inc.
A head-to-head of AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | ABBV | GILD |
|---|---|---|
| Market Cap | $355.43B | $166.72B |
| P/E (TTM) | 125.36 | 18.29 |
| Forward P/E | 15.23 | 13.46 |
| P/S | 5.66 | 5.61 |
| P/B | -57.26 | 7.12 |
| EV/EBITDA | 24.76 | 12.15 |
| Dividend Yield | 2.52% | 2.42% |
| Profit Margin | 5.79% | 30.99% |
| Gross Margin | 70.24% | 78.83% |
| Operating Margin | 32.85% | 39.74% |
| Revenue Growth (YoY) | +12.43% | +4.39% |
| FCF Yield | 5.62% | 6.13% |
| Debt / Equity | — | 94.64 |
| Current Ratio | 0.80 | 1.97 |
Which is better: AbbVie Inc. or Gilead Sciences, Inc.?
- ✓Larger by market cap: AbbVie Inc.
- ✓Cheaper valuation (lower P/E): Gilead Sciences, Inc.
- ✓Higher dividend yield: AbbVie Inc.
- ✓More profitable (net margin): Gilead Sciences, Inc.
- ✓Faster revenue growth: AbbVie Inc.
- ✓Higher free-cash-flow yield: Gilead Sciences, Inc.
Across 11 available metrics, Gilead Sciences, Inc. leads 9–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare AbbVie Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.